Vaccines are important for protecting individuals at increased risk of severe infections,
including patients undergoing DMARD therapy. However, DMARD therapy can also …

Patients with autoimmune inflammatory rheumatic diseases (AIIRDs) are at increased risk
for severe infections. Vaccine responses and safety profiles may differ between AIIRD …

Objectives To characterize the kinetics of humoral and T-cell responses in rheumatoid
arthritis (RA)-patients followed up to 4-6 weeks (T3) after the SARS-CoV-2 vaccine booster …

Objectives Humoral vaccine responses to SARS-CoV-2 vaccines are impaired and short
lasting in patients with immune-mediated inflammatory diseases (IMID) following two …

Background The impact of immunosuppressive therapies on the efficacy of vaccines to
SARS-CoV-2 is not completely clarified. We analyzed humoral and T cell-mediated …

Background Data on response and safety of repeated vaccinations and hybrid immunity in
patients with immune-mediated inflammatory diseases on immunosuppressive therapy is …

Objective The level of neutralising capacity against Omicron BA. 1 and BA. 2 after third
COVID-19 vaccination in patients on paused or continuous methotrexate (MTX) therapy is …

Objectives A third COVID-19 vaccination is recommended for immunosuppressed patients.
However, data on immunogenicity and safety of a third COVID-19 vaccination in patients …

Background The durability of vaccine-induced humoral immunity against SARS-CoV-2 in
patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive …

Immune-mediated inflammatory diseases (IMIDs) are a highly heterogeneous group of
diseases that share a common etiology of immune dysregulation, such as rheumatoid …